GlassScriptPhysician profile
Archana K Shah
NPI 1124096391
$14,095.58
in general payments reported to CMS, 2019-2025
34 companies · $2,104 in 2025
The $2,104 reported for 2025 was more than what 86% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,845 · 2020: $1,452 · 2021: $1,803 · 2022: $2,575 · 2023: $1,808 · 2024: $1,509 · 2025: $2,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,352 · Education: $68.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,352.18 |
| Education | $68.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $3,263.81 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $1,777.61 | 2019-2025 | Biktarvy |
| Insmed, INC. | $1,426.65 | 2019-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $1,209.59 | 2019-2025 | Dificid, Zerbaxa, Pifeltro |
| Janssen Biotech, INC. | $996.52 | 2019-2023 | Symtuza, Prezcobix |
| La Jolla Pharmaceutical Company | $934.27 | 2021-2025 | Xerava, Xacduro, Zevtera |
| Melinta Therapeutics, LLC | $913.05 | 2019-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Paratek Pharmaceuticals, INC. | $759.06 | 2021-2025 | Nuzyra |
| Shionogi INC | $451.96 | 2020-2025 | Fetroja |
| Janssen Products, LP | $325.20 | 2019-2022 | |
| Astellas Pharma US INC | $317.37 | 2020-2025 | Cresemba |
| Abbvie INC. | $223.85 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $182.63 | 2020-2022 | |
| Cumberland Pharmaceuticals, INC. | $181.86 | 2023-2025 | Vibativ |
| Allergan, INC. | $170.49 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $134.72 | 2019-2025 | Collagenase Santyl, Renasys Touch, Renasys Go V2 Home |
| Tetraphase Pharmaceuticals, INC. | $133.54 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $122.63 | 2019-2020 | |
| Napo Pharmaceuticals INC | $109.08 | 2019-2025 | Mytesi |
| Grifols USA, LLC | $74.21 | 2022-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $73.29 | 2022-2025 | Cuvitru |
| Pfizer INC. | $42.11 | 2022-2025 | |
| Shire North American Group INC | $35.78 | 2019 | |
| Theratechnologies INC. | $29.94 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $27.58 | 2024-2025 | Rebyota |
| Nabriva Therapeutics, Plc | $27.01 | 2020-2021 | |
| Mylan Pharmaceuticals INC. | $24.11 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.81 | 2025 | Xifaxan |
| Invivyd INC | $19.60 | 2024 | Pemgarda |
| Advanced Oxygen Therapy INC. | $19.33 | 2025 | Topical Oxygen Chamber For Extremities |
| Mallinckrodt Hospital Products INC. | $18.69 | 2024 | Terlivaz |
| Cipher Pharmaceuticals US LLC | $16.65 | 2025 | Natroba, Spinosad |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Emd Serono, INC. | $13.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archana Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.